Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 1/20 | 0.55 |
| ▸ | SELE | P16581 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | FGF1 | P05230 | 1/20 | 0.46 |
| ▸ | FGF2 | P09038 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717956 | 0.94 | MAG (0.58) | MAGLGALS3LGALS8LGALS4LGALS7; LGALS7B | |
| SCHEMBL7717946 | 0.94 | MAG (0.58) | MAGLGALS3LGALS8LGALS4LGALS7; LGALS7B | |
| SCHEMBL542355 | 0.94 | MAG (0.58) | MAGLGALS3LGALS8LGALS4LGALS7; LGALS7B | |
| SCHEMBL542353 | 0.94 | MAG (0.58) | MAGLGALS3LGALS8LGALS4LGALS7; LGALS7B | |
| SCHEMBL16153923 | 0.94 | MAG (0.58) | MAGLGALS3LGALS8LGALS4LGALS7; LGALS7B | |
| SCHEMBL5841546 | 0.88 | MAG (0.55) | MAGLGALS3LGALS8SLC6A2L3MBTL1 | |
| SCHEMBL5841006 | 0.88 | MAG (0.55) | MAGLGALS3LGALS8SLC6A2L3MBTL1 | |
| SCHEMBL22204678 | 0.88 | MAG (0.55) | MAGLGALS3LGALS8SLC6A2L3MBTL1 | |
| SCHEMBL5841001 | 0.88 | MAG (0.55) | MAGLGALS3LGALS8SLC6A2L3MBTL1 | |
| SCHEMBL4275701 | 0.85 | MAG (0.54) | MAGLGALS3LGALS8LGALS7; LGALS7BLGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633376-B2 | System and method for risk assessment of autism spectrum disorder | TATA CONSULTANCY SERVICES LIMITED (IN) | 2026-05-19 | — | — | US | disclosed |
| US-20250356948-A1 | SYSTEM AND METHOD FOR RISK ASSESSMENT OF AUTISM SPECTRUM DISORDER | TATA CONSULTANCY SERVICES LIMITED (IN) | 2025-11-20 | — | — | US | disclosed |
| EP-4009970-B1 | SYSTEM AND METHOD FOR RISK ASSESSMENT OF AUTISM SPECTRUM DISORDER | TATA CONSULTANCY SERVICES LTD (IN) | 2024-07-31 | — | — | EP | disclosed |
| US-20220293277-A1 | SYSTEM AND METHOD FOR RISK ASSESSMENT OF PARKINSONS DISEASE | TATA CONSULTANCY SERVICES LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12633376-B2 | System and method for risk assessment of autism spectrum disorder | TPH1, KYNU, TPH2 | MAG 2434/4885SELE 4125/4885LGALS3 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.